Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference

Tuesday, September 30, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

CAMBRIDGE, Mass., Sept. 30 Verenium Corporation(Nasdaq: VRNM), a pioneer in the development of next-generation cellulosicethanol and high-performance specialty enzymes, announced today that JanetRoemer, Executive Vice President and General Manager, Specialty EnzymesBusiness, will present at the upcoming William Blair & Company 2008 Small-CapGrowth Stock Conference. The presentation is scheduled to begin at 10:40 a.m.ET on Tuesday, October 7, 2008 and will take place at The Waldorf-AstoriaHotel in New York City.

More information about this event, including a live webcast, may beaccessed by visiting the "Investors" section of Verenium's website at A webcast replay will be available approximately onehour after the live webcast ends and will be accessible for one monthfollowing the conference.

About Verenium

Verenium Corporation is a leader in the development and commercializationof cellulosic ethanol, an environmentally-friendly and renewabletransportation fuel, as well as high-performance specialty enzymes forapplications within the biofuels, industrial, and health and nutritionmarkets. The Company possesses integrated, end-to-end capabilities inpre-treatment, novel enzyme development, fermentation, engineering, andproject development and is moving rapidly to commercialize its proprietarytechnology for the production of ethanol from a wide array of feedstocks,including sugarcane bagasse, dedicated energy crops, agricultural waste, andwood products. In addition to the vast potential for biofuels, a multitude oflarge-scale industrial opportunities exist for the Company for productsderived from the production of low-cost, biomass-derived sugars. Verenium'sSpecialty Enzyme business harnesses the power of enzymes to create a broadrange of specialty products to meet high-value commercial needs. Verenium'sworld class R&D organization is renowned for its capabilities in the rapidscreening, identification, and expression of enzymes-proteins that act as thecatalysts of biochemical reactions. For more information on Verenium, visit

Forward Looking Statements

Statements in this press release that are not strictly historical are"forward-looking" and involve a high degree of risk and uncertainty. Theseinclude statements related to the Company's operations, capabilities,commercialization activities, target markets and cellulosic ethanolfacilities, all of which are prospective. Such statements are onlypredictions, and actual events or results may differ materially from thoseprojected in such forward-looking statements. Factors that could cause orcontribute to the differences include, but are not limited to, risksassociated with Verenium's new and uncertain technologies, risks associatedwith the costs, labor requirements and labor availability associated withVerenium's demonstration plant, risks associated with Verenium's ability toobtain additional capital to support its planned operations, risks associatedwith Verenium's dependence on patents and proprietary rights, risks associatedwith Verenium's protection and enforcement of its patents and proprietaryrights, technological, regulatory, competitive and other risks related todevelopment, production, and commercialization of cellulosic ethanol and otherbiofuels and the commercial prospects of those industries, Verenium'sdependence on existing collaboration, manufacturing, and/or licenseagreements, and its ability to achieve milestones under existing and futurecollaboration agreements, the ability of Verenium and its partners tocommercialize products (including by obtaining any required regulatoryapprovals) using Verenium's technologies and timing for launching anycommercialized products, the ability of Verenium and its collaborators tomarket and sell any products that it or they commercialize, the development oravailability of competitive products or technologies, the future ability ofVerenium to enter into and/or maintain collaboration and joint ventureagreements and licenses, changes in the U.S. or global energy markets and lawsand regulations applicable to them, and risks and other uncertainties morefully described in the Company's filings with the Securities and ExchangeCommission, including, but not limited to, the Company's quarterly report onForm 10-Q for the three months ended June 30, 2008. These forward-lookingstatements speak only as of the date hereof. The Company expressly disclaimsany intent or obligation to update these forward-looking statements.Contacts: Sarah Carmody Sr. Corporate Communications Associate 617-674-5357

SOURCE Verenium Corporation

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store